ClinicalTrials.gg
TerminatedNCT05655299Serenity PsOUpdated Nov 19, 2026Results posted

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

A Phase 2 interventional study of Placebo and VTX958 in Psoriasis, sponsored by Ventyx Biosciences, Inc. Terminated at 63 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Ventyx Biosciences, Inc (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Business Decision
Updated Nov 19, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.

Enrollment
13th of 36
222 · median 181
Started
2022
the only one that year
Phase 2
9 of 36
none open now
Registered
30th of 36
by date

Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 13th largest by enrollment, is the only one that started in 2022, is one of 9 in phase 2, and was the 30th registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Psoriasis by Eli Lilly and Company, or all of them as a file.
02

Study summary

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.

The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • TYK2 inhibitor
  • moderate to severe psoriasis
  • Ventyx
  • VTX958
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participant aged 18 years or older.
  • History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
  • Has had stable psoriasis conditions for at least 3 months before screening.
  • Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
  • Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
  • Deemed by the investigator to be eligible for phototherapy or systemic therapy.
  • Females of must agree to use a highly effective method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.

Exclusion criteria

Exclusion Criteria:

  • Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
  • Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
  • History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Participant is known to have immune deficiency or is .
  • Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including , immunosuppressants, or biologics).

Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.

  • Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], Janus kinase [JAK] inhibitors, or tar) within 2 weeks prior to Day 1.
  • Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.

Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.

  • Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
  • Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
  • Participant has received treatment with an or marketed TYK2 inhibitor.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    VTX958 300 mg BID (Placebo Controlled)

    Participants received one 300 milligram (mg) VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1.

    Drug: VTX958

  • Experimental
    VTX958 225 mg BID (PC)

    Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.

    Drug: VTX958

  • Experimental
    VTX958 300 mg QD (PC)

    Participants received 300 mg VTX958 tablet administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1.

    Drug: VTX958

  • Experimental
    VTX958 50 mg BID (PC)

    Participants received 50 mg VTX958 tablet administered orally BID and matching placebo tablets administered orally BID to maintain the blind in Period 1.

    Drug: VTX958

  • Placebo comparator
    Placebo BID (PC)

    Participants received placebo tablets matched to VTX958, administered BID to maintain the blind in Period 1.

    Drug: Placebo

  • Experimental
    Long Term Extension Period (LTE): VTX958 300 mg BID

    Participants who received 300 mg VTX958 dose administered orally BID in Period 2.

    Drug: VTX958

  • Experimental
    LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID

    Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2.

    Drug: VTX958

  • Experimental
    LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD

    Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2.

    Drug: VTX958

  • Experimental
    LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID

    Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2.

    Drug: VTX958

  • Experimental
    Open Label Extension (OLE): VTX958 300 mg BID

    Participants who received 300 mg VTX958 dose administered orally BID in Period 3.

    Drug: VTX958

Interventions

  • DrugPlacebo

    Placebo administered orally

  • DrugVTX958

    VTX958 administered orally

06

What researchers measure

Primary outcomes

  1. Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16

    Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.

    Time frame: Week 16

  2. Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958

    The number of participants with TEAEs and SAEs observed during the study of VTX958. A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated). An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences: * Results in death * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect

    Time frame: Baseline up to week 16

Secondary outcomes

  1. Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16

    Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur 1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling 2. = Mild: Pink to light red color; slight thickening; mainly fine scaling 3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling 4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions

    Time frame: Week 16

  2. Period 1: Change From Baseline in PASI Score at Week 16

    Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Baseline, Week 16

  3. Period 1: Percent Change From Baseline in PASI Score at Week 16

    Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Baseline, Week 16

  4. Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16

    Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 16

  5. Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16

    Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

    Time frame: Week 16

  6. Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks

    The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.

    Time frame: Baseline, Week 16

  7. Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16

    Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

    Time frame: Baseline, Week 16

07

Results

Posted Nov 19, 2026

Participant flow

Period 1: Placebo Controlled (PC)
Participant flow — Period 1: Placebo Controlled (PC)
MilestoneVTX958 300 mg BID [Placebo Controlled Period (PC)]VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Long Term Extension Period (LTE): VTX958 300 mg BIDLTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BIDVTX958 300 mg QD (PC)/ VTX958 300 mg QDVTX958 50 mg BID (PC)/ VTX958 50 mg BIDOpen Label Extension (OLE): VTX958 300 mg BID
Started444544454400000
All randomised participants who received at least 1 dose of study intervention434544454300000
Completed343538403600000
Not completed101065800000
Withdrew: Withdrawal by subject4223300000
Withdrew: Lost to follow-up1321300000
Withdrew: Adverse event5521100000
Withdrew: Lack of efficacy0000100000
Period 2: Long Term Extension (LTE)
Participant flow — Period 2: Long Term Extension (LTE)
MilestoneVTX958 300 mg BID [Placebo Controlled Period (PC)]VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Long Term Extension Period (LTE): VTX958 300 mg BIDLTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BIDVTX958 300 mg QD (PC)/ VTX958 300 mg QDVTX958 50 mg BID (PC)/ VTX958 50 mg BIDOpen Label Extension (OLE): VTX958 300 mg BID
Started000001342014110
Lte safety set000001322115110
Completed00000231310
Not completed000001111911100
Withdrew: Withdrawal by subject0000070010
Withdrew: Lost to follow-up0000030000
Withdrew: Pregnancy0000010000
Withdrew: Adverse event0000010000
Withdrew: Physician decision0000020000
Withdrew: Study terminated by sponsor0000095191080
Withdrew: Lack of efficacy0000020110
Period 3: Open Label Extension (OLE)
Participant flow — Period 3: Open Label Extension (OLE)
MilestoneVTX958 300 mg BID [Placebo Controlled Period (PC)]VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Long Term Extension Period (LTE): VTX958 300 mg BIDLTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BIDVTX958 300 mg QD (PC)/ VTX958 300 mg QDVTX958 50 mg BID (PC)/ VTX958 50 mg BIDOpen Label Extension (OLE): VTX958 300 mg BID
Started00000000027
Completed0000000000
Not completed00000000027
Withdrew: Withdrawal by subject0000000001
Withdrew: Study terminated by sponsor00000000026

Outcome measures

PrimaryPeriod 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16

Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity. As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
percentage of participantsVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 1648.848.931.824.414.0
Statistical analysis
  • VTX958 300 mg BID (PC) vs Placebo BID (PC) · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 5.77 · 95% CI 2.013 to 16.531
  • VTX958 225 mg BID (PC) vs Placebo BID (PC) · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 6.05 · 95% CI 2.086 to 17.542
  • VTX958 300 mg QD (PC) vs Placebo BID (PC) · Cochran-Mantel-Haenszel · p = 0.045 · Odds ratio (or): 3.00 · 95% CI 1.002 to 8.980
  • VTX958 50 mg BID (PC) vs Placebo BID (PC) · Cochran-Mantel-Haenszel · p = 0.200 · Odds ratio (or): 2.09 · 95% CI 0.673 to 6.517
PrimaryPeriod 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958

The number of participants with TEAEs and SAEs observed during the study of VTX958. A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated). An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences: * Results in death * Is life-threatening * Requires in-patient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect

Time frame:
Baseline up to week 16
Reported as:
Count of participants · Participants
Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958
ParticipantsVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
TEAE's2528201718
SAE's10111
SecondaryPeriod 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16

Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe): 0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur 1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling 2. = Mild: Pink to light red color; slight thickening; mainly fine scaling 3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling 4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16
percentage of participantsVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 1637.240.020.513.37.0
SecondaryPeriod 1: Change From Baseline in PASI Score at Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Period 1: Change From Baseline in PASI Score at Week 16
score on a scaleVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Change From Baseline in PASI Score at Week 16-13.58 ± 1.160-13.20 ± 1.144-9.79 ± 1.123-7.88 ± 1.115-5.81 ± 1.162
SecondaryPeriod 1: Percent Change From Baseline in PASI Score at Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · Percent change
Period 1: Percent Change From Baseline in PASI Score at Week 16
Percent changeVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Percent Change From Baseline in PASI Score at Week 16-74.94 ± 5.365-72.18 ± 5.290-54.82 ± 5.186-45.22 ± 5.155-33.44 ± 5.356
SecondaryPercentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16

Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16
percentage of participantsVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 1641.937.815.911.14.7
SecondaryPeriod 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16

Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16
percentage of participantsVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 1614.015.62.34.40
SecondaryPeriod 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks

The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · score on a scale
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks
score on a scaleVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks-7.2 ± 0.90-8.1 ± 0.88-5.4 ± 0.86-4.4 ± 0.86-3.1 ± 0.89
SecondaryPeriod 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value. BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · percentage of BSA
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16
percentage of BSAVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16-13.48 ± 1.797-13.82 ± 1.771-9.56 ± 1.739-4.94 ± 1.725-3.82 ± 1.800

Adverse events

Collected over Baseline up to 76 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VTX958 300 mg BID (PC)0/43 (0%)1/43 (2.3%)15/43 (34.9%)
VTX958 225 mg BID (PC)0/45 (0%)0/45 (0%)10/45 (22.2%)
VTX958 300 mg QD (PC)0/44 (0%)1/44 (2.3%)8/44 (18.2%)
VTX958 50 mg BID (PC)0/45 (0%)1/45 (2.2%)5/45 (11.1%)
Placebo BID (PC)0/43 (0%)1/43 (2.3%)5/43 (11.6%)
Long Term Extension Period (LTE): VTX958 300 mg BID0/132 (0%)4/132 (3%)24/132 (18.2%)
LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID0/21 (0%)0/21 (0%)3/21 (14.3%)
VTX958 300 mg QD (PC)/ VTX958 300 mg QD0/15 (0%)1/15 (6.7%)4/15 (26.7%)
VTX958 50 mg BID (PC)/ VTX958 50 mg BID0/11 (0%)0/11 (0%)1/11 (9.1%)
Open Label Extension (OLE): VTX958 300 mg BID0/27 (0%)0/27 (0%)2/27 (7.4%)
Most frequent serious events
Most frequent serious events
EventVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Long Term Extension Period (LTE): VTX958 300 mg BIDLTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BIDVTX958 300 mg QD (PC)/ VTX958 300 mg QDVTX958 50 mg BID (PC)/ VTX958 50 mg BIDOpen Label Extension (OLE): VTX958 300 mg BID
Brain injuryNervous system disorders0/430/450/440/450/430/1320/211/150/110/27
Coronary artery diseaseCardiac disorders0/430/450/440/451/431/1320/210/150/110/27
Myocardial infarctionCardiac disorders0/430/450/440/451/430/1320/210/150/110/27
AppendicitisInfections and infestations1/430/450/440/450/430/1320/210/150/110/27
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/430/451/440/450/430/1320/210/150/110/27
VomitingGastrointestinal disorders0/430/450/441/450/430/1320/210/150/110/27
Cyclic vomiting syndromeGastrointestinal disorders0/430/450/440/450/431/1320/210/150/110/27
Chest painGeneral disorders0/430/450/440/450/431/1320/210/150/110/27
Clavicle fractureInjury, poisoning and procedural complications0/430/450/440/450/431/1320/210/150/110/27
HeadacheNervous system disorders0/430/450/440/450/431/1320/210/150/110/27
Most frequent other events
Showing 10 of 13
Most frequent other events
EventVTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Long Term Extension Period (LTE): VTX958 300 mg BIDLTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BIDVTX958 300 mg QD (PC)/ VTX958 300 mg QDVTX958 50 mg BID (PC)/ VTX958 50 mg BIDOpen Label Extension (OLE): VTX958 300 mg BID
Alanine aminotransferase increasedInvestigations6/432/453/440/450/435/1320/210/150/110/27
Upper respiratory tract infectionInfections and infestations5/433/453/441/451/435/1322/211/150/111/27
Aspartate aminotransferase increasedInvestigations4/430/451/440/451/435/1320/210/150/110/27
Back painMusculoskeletal and connective tissue disorders0/430/450/441/450/430/1320/210/151/110/27
Blood creatine phosphokinase increasedInvestigations3/430/450/440/452/434/1320/210/150/110/27
CataractEye disorders0/430/450/440/450/430/1320/211/150/110/27
NauseaGastrointestinal disorders2/431/450/443/450/431/1320/210/150/110/27
FallInjury, poisoning and procedural complications0/430/450/440/450/430/1320/211/150/110/27
Blood creatinine increasedInvestigations0/430/450/440/450/430/1320/211/150/110/27
GoutMetabolism and nutrition disorders0/430/451/440/450/430/1320/211/150/110/27

Baseline characteristics

All randomized participants who received at least 1 dose of study intervention.

Age, Categorical
Age, Categorical(Participants)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
<=18 years000000
Between 18 and 65 years3840394240199
>=65 years5553321
Age, Continuous
Age, Continuous(Years)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
Mean43.5 ± 13.7745.0 ± 14.5446.2 ± 12.6745.7 ± 13.1044.2 ± 13.0544.9 ± 13.36
Sex: Female, Male
Sex: Female, Male(Participants)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
Female141314171573
Male2932302828147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
Hispanic or Latino612107439
Not Hispanic or Latino3733343839181
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
American Indian or Alaska Native000000
Asian2134212
Native Hawaiian or Other Pacific Islander000011
Black or African American2321614
White3941384033191
More than one race001012
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(Participants)VTX958 300 mg BID (PC)VTX958 225 mg BID (PC)VTX958 300 mg QD (PC)VTX958 50 mg BID (PC)Placebo BID (PC)Total
Canada611810742
Poland221111121773
United States1523252319105
08

Study locations

63 sites
  • Local Site # 840012
    Birmingham, Alabama 35205, United States
  • Local Site # 840006
    Birmingham, Alabama 35244, United States
  • Local Site # 840028
    Phoenix, Arizona 85032, United States
  • Local Site # 840032
    Bryant, Arkansas 72022, United States
  • Local Site # 840041
    North Little Rock, Arkansas 72117, United States
  • Local Site # 840031
    Fountain Valley, California 92708, United States
  • Local Site # 840026
    Lomita, California 90717, United States
  • Local Site # 840019
    Santa Rosa, California 95405, United States
  • Local Site # 840003
    Sherman Oaks, California 91403, United States
  • Local Site # 840040
    Boca Raton, Florida 33486, United States
  • Local Site # 840011
    Doral, Florida 33122, United States
  • Local Site # 840023
    Hialeah, Florida 33012, United States
  • Local Site # 840021
    Miami Lakes, Florida 33104, United States
  • Local Site # 840044
    North Miami Beach, Florida 33162, United States
  • Local Site # 840010
    Ocala, Florida 34470, United States
  • Local Site # 840004
    Tampa, Florida 33607, United States
  • Local Site # 840001
    Tampa, Florida 33613, United States
  • Local Site # 840045
    West Palm Beach, Florida 33406, United States
  • Local Site # 840029
    Marietta, Georgia 30060, United States
  • Local Site # 840035
    Clarksville, Indiana 47129, United States
  • Local Site # 840005
    Indianapolis, Indiana 46250, United States
  • Local Site # 840030
    Plainfield, Indiana 46168, United States
  • Local Site # 840013
    Louisville, Kentucky 40241, United States
  • Local Site # 840022
    Rockville, Maryland 20850, United States
  • Local Site # 840008
    Brighton, Massachusetts 02135, United States
  • Local Site # 840016
    Bay City, Michigan 48706, United States
  • Local Site # 840007
    Fort Gratiot, Michigan 48059, United States
  • Local Site # 840002
    Troy, Michigan 48084, United States
  • Local Site # 840034
    New Brighton, Minnesota 55112, United States
  • Local Site # 840024
    Saint Joseph, Missouri 64506, United States
  • Local Site # 840027
    Portsmouth, New Hampshire 03801, United States
  • Local Site # 840042
    Wilmington, North Carolina 28405, United States
  • Local Site # 840037
    Mason, Ohio 45040, United States
  • Local Site # 840009
    Portland, Oregon 97223, United States
  • Local Site # 840038
    Rapid City, South Dakota 57702, United States
  • Local Site # 840015
    Murfreesboro, Tennessee 37130, United States
  • Local Site # 840039
    Pflugerville, Texas 78660, United States
  • Local Site # 840014
    Spokane, Washington 99202, United States
  • Local Site # 124012
    Fredericton, Canada
  • Local Site # 124010
    Mississauga, Canada
  • Local Site # 124002
    Montreal, Canada
  • Local Site # 124004
    North Bay, Canada
  • Local Site # 124011
    Oshawa, Canada
  • Local Site # 124007
    Peterborough, Canada
  • Local Site # 124008
    Québec, Canada
  • Local Site # 124005
    Toronto, Canada
  • Local Site # 124006
    Windsor, Canada
  • Local Site # 616015
    Bialystok, Poland
  • Local Site # 616016
    Bialystok, Poland
  • Local Site # 616001
    Katowice, Poland
  • Local Site # 616014
    Krakow, Poland
  • Local Site # 616004
    Lodz, Poland
  • Local Site #616010
    Lublin, Poland
  • Local Site # 616011
    Mikołów, Poland
  • Local Site # 616009
    Nowa Sól, Poland
  • Local Site # 616003
    Ostrowiec Świętokrzyski, Poland
  • Local Site # 616008
    Poznan, Poland
  • Local Site # 616007
    Szczecin, Poland
  • Local Site # 616013
    Szczecin, Poland
  • Local Site # 616005
    Warsaw, Poland
  • Local Site # 616002
    Wroclaw, Poland
  • Local Site # 616006
    Wroclaw, Poland
  • Local Site # 616018
    Wroclaw, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Sep 2023, 10 months.

Results were first posted in Nov 2026, 3 years 1 month after primary completion. A results delay was requested in Sep 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2022
First posted
Dec 19, 2022
StartActual
Nov 17, 2022
Primary completionActual
Sep 25, 2023
CompletionActual
Dec 20, 2023
Results delay requested
Sep 12, 2024
Results first posted
Nov 19, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 19, 2026
Sites
11 sites added, 11 sites removed
Show 11 added (9 Poland, 2 Canada)
  • Local Site # 124002 · Montreal, Canada
  • Local Site # 124008 · Québec, Canada
  • Local Site # 616015 · Bialystok, Poland
  • Local Site # 616016 · Bialystok, Poland
  • Local Site # 616014 · Krakow, Poland
  • Local Site # 616004 · Lodz, Poland
  • Local Site # 616008 · Poznan, Poland
  • Local Site # 616005 · Warsaw, Poland
  • Local Site # 616002 · Wroclaw, Poland
  • Local Site # 616006 · Wroclaw, Poland
  • Local Site # 616018 · Wroclaw, Poland
Show 11 removed
  • Local Site # 124002 · Montréal, Canada
  • Local Site # 124008 · Québec City, Canada
  • Local Site # 616015 · Białystok, Poland
  • Local Site # 616016 · Białystok, Poland
  • Local Site # 616014 · Kraków, Poland
  • Local Site # 616008 · Poznań, Poland
  • Local Site # 616005 · Warszawa, Poland
  • Local Site # 616002 · Wrocław, Poland
  • Local Site # 616006 · Wrocław, Poland
  • Local Site # 616018 · Wrocław, Poland
  • Local Site # 616004 · Łódź, Poland
Nov 19, 2026
Interventions
Changed VTX958 Dose A→VTX958. Removed Drug: VTX958 Dose B·Drug: VTX958 Dose C·Drug: VTX958 Dose D. Arms added: VTX958 300 mg BID (Placebo Controlled)·VTX958 225 mg BID (PC)·VTX958 300 mg QD (PC)·VTX958 50 mg BID (PC)·Placebo BID (PC)·and 5 more
All 10

VTX958 300 mg BID (Placebo Controlled) · VTX958 225 mg BID (PC) · VTX958 300 mg QD (PC) · VTX958 50 mg BID (PC) · Placebo BID (PC) · Long Term Extension Period (LTE): VTX958 300 mg BID · LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID · LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD · LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID · Open Label Extension (OLE): VTX958 300 mg BID

; arms removed: VTX958 Dose A·VTX958 Dose B·VTX958 Dose C·VTX958 Dose D·Placebo
Nov 19, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPeriod 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) Efficacy at Week 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Week 16
  • ChangedBefore Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate through study completionNow Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958Time frame: Screening through study completion, up to 76 weeks → Baseline up to week 16
Nov 19, 2026
Documents
Secondary outcomes
2 edited, 5 added, 4 removed
What changed in the outcomes
  • EditedPeriod 1: Change From Baseline in Dermatology Life Quality Index (DLQI) Efficacy at 16 weeksWeeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Baseline, Week 16
  • EditedPeriod 1: Change From Baseline in the Percentage of Body Surface Area (BSA) EfficacyAffected at Week 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Baseline, Week 16
  • AddedPeriod 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16Time frame: Week 16
  • AddedPeriod 1: Change From Baseline in PASI Score at Week 16Time frame: Baseline, Week 16
  • AddedPeriod 1: Percent Change From Baseline in PASI Score at Week 16Time frame: Baseline, Week 16
  • AddedPercentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16Time frame: Week 16
  • AddedPeriod 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16Time frame: Week 16
  • RemovedStatic Physician's Global Assessment (sPGA) Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
  • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
  • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
  • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Results posted
    11 sites added, 11 sites removed
    Show 11 added (9 Poland, 2 Canada)
    • Local Site # 124002 · Montreal, Canada
    • Local Site # 124008 · Québec, Canada
    • Local Site # 616015 · Bialystok, Poland
    • Local Site # 616016 · Bialystok, Poland
    • Local Site # 616014 · Krakow, Poland
    • Local Site # 616004 · Lodz, Poland
    • Local Site # 616008 · Poznan, Poland
    • Local Site # 616005 · Warsaw, Poland
    • Local Site # 616002 · Wroclaw, Poland
    • Local Site # 616006 · Wroclaw, Poland
    • Local Site # 616018 · Wroclaw, Poland
    Show 11 removed
    • Local Site # 124002 · Montréal, Canada
    • Local Site # 124008 · Québec City, Canada
    • Local Site # 616015 · Białystok, Poland
    • Local Site # 616016 · Białystok, Poland
    • Local Site # 616014 · Kraków, Poland
    • Local Site # 616008 · Poznań, Poland
    • Local Site # 616005 · Warszawa, Poland
    • Local Site # 616002 · Wrocław, Poland
    • Local Site # 616006 · Wrocław, Poland
    • Local Site # 616018 · Wrocław, Poland
    • Local Site # 616004 · Łódź, Poland
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPeriod 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) Efficacy at Week 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Week 16
    • ChangedBefore Adverse Event (AE) / Serious Adverse Event (SAE) Incidence Rate through study completionNow Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958Time frame: Screening through study completion, up to 76 weeks → Baseline up to week 16
    Secondary outcomes 2 edited, 5 added, 4 removed
    What changed in the outcomes
    • EditedPeriod 1: Change From Baseline in Dermatology Life Quality Index (DLQI) Efficacy at 16 weeksWeeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Baseline, Week 16
    • EditedPeriod 1: Change From Baseline in the Percentage of Body Surface Area (BSA) EfficacyAffected at Week 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16 → Baseline, Week 16
    • AddedPeriod 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16Time frame: Week 16
    • AddedPeriod 1: Change From Baseline in PASI Score at Week 16Time frame: Baseline, Week 16
    • AddedPeriod 1: Percent Change From Baseline in PASI Score at Week 16Time frame: Baseline, Week 16
    • AddedPercentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16Time frame: Week 16
    • AddedPeriod 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16Time frame: Week 16
    • RemovedStatic Physician's Global Assessment (sPGA) Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
    • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
    • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
    • RemovedPASI Efficacy at 16 weeksTime frame: Day 1 of Placebo-controlled treatment period to week 16
    Interventions Changed VTX958 Dose A→VTX958. Removed Drug: VTX958 Dose B·Drug: VTX958 Dose C·Drug: VTX958 Dose D. Arms added: VTX958 300 mg BID (Placebo Controlled)·VTX958 225 mg BID (PC)·VTX958 300 mg QD (PC)·VTX958 50 mg BID (PC)·Placebo BID (PC)·and 5 more
    All 10

    VTX958 300 mg BID (Placebo Controlled) · VTX958 225 mg BID (PC) · VTX958 300 mg QD (PC) · VTX958 50 mg BID (PC) · Placebo BID (PC) · Long Term Extension Period (LTE): VTX958 300 mg BID · LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID · LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD · LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID · Open Label Extension (OLE): VTX958 300 mg BID

    ; arms removed: VTX958 Dose A·VTX958 Dose B·VTX958 Dose C·VTX958 Dose D·Placebo
    + 4 other changes: identifiers, verification date, registry dates and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05655299
Responsible party
Sponsor
First posted
Dec 19, 2022
Start date
Nov 17, 2022
Primary completion
Sep 25, 2023
Completion
Dec 20, 2023
Results posted
Nov 19, 2026
Last update
Nov 19, 2026

Study contacts

Snehal Naik, PhD
study director · Ventyx Biosciences, Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion